Literature DB >> 23499601

The test-negative design for estimating influenza vaccine effectiveness.

Michael L Jackson1, Jennifer C Nelson.   

Abstract

OBJECTIVE: The test-negative design has emerged in recent years as the preferred method for estimating influenza vaccine effectiveness (VE) in observational studies. However, the methodologic basis of this design has not been formally developed.
METHODS: In this paper we develop the rationale and underlying assumptions of the test-negative study. Under the test-negative design for influenza VE, study subjects are all persons who seek care for an acute respiratory illness (ARI). All subjects are tested for influenza infection. Influenza VE is estimated from the ratio of the odds of vaccination among subjects testing positive for influenza to the odds of vaccination among subjects testing negative.
RESULTS: With the assumptions that (a) the distribution of non-influenza causes of ARI does not vary by influenza vaccination status, and (b) VE does not vary by health care-seeking behavior, the VE estimate from the sample can generalized to the full source population that gave rise to the study sample. Based on our derivation of this design, we show that test-negative studies of influenza VE can produce biased VE estimates if they include persons seeking care for ARI when influenza is not circulating or do not adjust for calendar time.
CONCLUSIONS: The test-negative design is less susceptible to bias due to misclassification of infection and to confounding by health care-seeking behavior, relative to traditional case-control or cohort studies. The cost of the test-negative design is the additional, difficult-to-test assumptions that incidence of non-influenza respiratory infections is similar between vaccinated and unvaccinated groups within any stratum of care-seeking behavior, and that influenza VE does not vary across care-seeking strata.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499601     DOI: 10.1016/j.vaccine.2013.02.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  166 in total

1.  Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013.

Authors:  Joshua G Petrie; Caroline Cheng; Ryan E Malosh; Jeffrey J VanWormer; Brendan Flannery; Richard K Zimmerman; Manjusha Gaglani; Michael L Jackson; Jennifer P King; Mary Patricia Nowalk; Joyce Benoit; Anne Robertson; Swathi N Thaker; Arnold S Monto; Suzanne E Ohmit
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

2.  Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons.

Authors:  Michael L Jackson; Lisa A Jackson; Burney Kieke; David McClure; Manjusha Gaglani; Kempapura Murthy; Ryan Malosh; Arnold Monto; Richard K Zimmerman; Ivo M Foppa; Brendan Flannery; Mark G Thompson
Journal:  Vaccine       Date:  2015-08-11       Impact factor: 3.641

3.  Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Authors:  Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

4.  Influenza vaccine effectiveness in older adults compared with younger adults over five seasons.

Authors:  Kate Russell; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Brendan Flannery
Journal:  Vaccine       Date:  2018-02-28       Impact factor: 3.641

Review 5.  Using Wolbachia for Dengue Control: Insights from Modelling.

Authors:  Ilaria Dorigatti; Clare McCormack; Gemma Nedjati-Gilani; Neil M Ferguson
Journal:  Trends Parasitol       Date:  2017-11-25

6.  Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

7.  Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.

Authors:  Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia
Journal:  JAMA Netw Open       Date:  2018-10-05

8.  Influenza Vaccine Effectiveness in Preventing Hospitalizations in Older Patients With Chronic Obstructive Pulmonary Disease.

Authors:  Andrea S Gershon; Hannah Chung; Joan Porter; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Aaron Campigotto; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew E Simor; Marek Smieja; George Zahariadis; Jeffrey C Kwong
Journal:  J Infect Dis       Date:  2020-01-01       Impact factor: 5.226

9.  Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States.

Authors:  Benjamin J Cowling; Shuo Feng; Lyn Finelli; Andrea Steffens; Ashley Fowlkes
Journal:  Vaccine       Date:  2015-11-21       Impact factor: 3.641

10.  Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses.

Authors:  Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.